Drug name
Last update: Sep 2026GS-1219
Developer(s)
Drug information
Not provided
GS-1219
Not applicable (investigational; no brand name assigned)
Small molecule
INSTI (Integrase strand transfer inhibitor)
Not provided
https://www.fiercebiotech.com/biotech/gilead-ends-ph-1-trial-after-settling-twice-yearly-treatment-partner-lenacapavir development paused as of July 2026: Deprioritised by Gilead as partner for LEN (NCT07115368) in favour of GS-3242
In phase 1, development terminated (last checked 18 Sept. 2026)
not yet approved.
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral
Associated long-acting platforms
Not provided
Use of drug
- To be determined
- Weekly
Dosage
to be determined
to be determined
to be determined
Development reported as paused by Gilead (https://www.gilead.com/science/pipeline; accessed Sep, 18, 2026)
Not provided
Related entries
Not provided
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL